Inhibition of HIV-1 Replication by SiRNA Targeting Conserved Regions of Gag/pol
Overview
Affiliations
Short interfering RNAs (siRNAs) targeting HIV-1gag, vif, tat, rev and host CD4 and CCR5 have been reported to inhibit HIV replication. However, the sequence divergence of HIV and the concentration dependence of siRNA activity represent significant challenges to RNAi mediated inhibition. To determine the parameters of RNAi in suppression of HIV-1 we screened seven siRNA candidates targeting highly conserved regions of gag/pol, based on target site GC content, for antiviral activity at varying concentrations. Only two of these inhibited CA-p24 production more than 50%, 2064 and 2161. Activity varied with concentration, with 100 nM producing optimal suppression. Requirements for target sequence conservation and activity over a range of concentrations may severely limit the number of siRNA candidates for therapeutic development.
Jai J, Shirleen D, Hanbali C, Wijaya P, Anginan T, Husada W J Genet Eng Biotechnol. 2022; 20(1):172.
PMID: 36576612 PMC: 9797628. DOI: 10.1186/s43141-022-00451-z.
CRISPR-Cas13a Inhibits HIV-1 Infection.
Yin L, Zhao F, Sun H, Wang Z, Huang Y, Zhu W Mol Ther Nucleic Acids. 2020; 21:147-155.
PMID: 32585623 PMC: 7321785. DOI: 10.1016/j.omtn.2020.05.030.
The therapeutic landscape of HIV-1 via genome editing.
Kwarteng A, Ahuno S, Kwakye-Nuako G AIDS Res Ther. 2017; 14(1):32.
PMID: 28705213 PMC: 5513397. DOI: 10.1186/s12981-017-0157-8.
Spanevello F, Calistri A, Del Vecchio C, Mantelli B, Frasson C, Basso G Mol Ther Nucleic Acids. 2016; 5:e312.
PMID: 27093170 PMC: 5014525. DOI: 10.1038/mtna.2016.24.
RNA interference approaches for treatment of HIV-1 infection.
Bobbin M, Burnett J, Rossi J Genome Med. 2015; 7(1):50.
PMID: 26019725 PMC: 4445287. DOI: 10.1186/s13073-015-0174-y.